Why the study?
Electrical storm has few established treatment options, and prospective multicentre evidence regarding the safety and effectiveness of percutaneous stellate ganglion block was lacking.
Does percutaneous stellate ganglion block (PSGB) reduce treated ventricular arrhythmic events by at least 50% within 12 hours in patients with refractory electrical storm?
Does percutaneous stellate ganglion block (PSGB) reduce treated ventricular arrhythmic events by at least 50% within 12 hours in patients with refractory electrical storm?
This large multicentre study demonstrates that percutaneous stellate ganglion block is a rapidly effective and safe neuromodulation therapy for reducing ventricular arrhythmia burden in patients with refractory electrical storm, even among those on anticoagulation or antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May support PSGB in refractory electrical storm; leaves open need for randomized confirmation.
BACKGROUND AND AIMS: An electrical storm (ES) is a clinical emergency with a paucity of established treatment options. Despite initial encouraging reports about the safety and effectiveness of percutaneous stellate ganglion block (PSGB), many questions remained unsettled and evidence from a prospective multicentre study was still lacking. For these purposes, the STAR study was designed. METHODS: This is a multicentre observational study enrolling patients suffering from an ES refractory to standard treatment from 1 July 2017 to 30 June 2023. The primary outcome was the reduction of treated arrhythmic events by at least 50% comparing the 12 h following PSGB with the 12 h before the procedure. STAR operators were specifically trained to both the anterior anatomical and the lateral ultrasound-guided approach. RESULTS: A total of 131 patients from 19 centres were enrolled and underwent 184 PSGBs. Patients were mainly male (83.2%) with a median age of 68 (63.8-69.2) years and a depressed left ventricular ejection fraction (25.0 ± 12.3%). The primary outcome was reached in 92% of patients, and the median reduction of arrhythmic episodes between 12 h before and after PSGB was 100% (interquartile range -100% to -92.3%). Arrhythmic episodes requiring treatment were significantly reduced comparing 12 h before the first PSGB with 12 h after the last procedure [six (3-15.8) vs. 0 (0-1), P < .0001] and comparing 1 h before with 1 h after each procedure [2 (0-6) vs. 0 (0-0), P < .001]. One major complication occurred (0.5%). CONCLUSIONS: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES.
No takes yet. Share an insight, caveat, or question.
Savastano et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: